Vnitr Lek 1992, 38(2):122-128

[Comparison of the effects of diltiazem and isradipine in adrenergic beta receptor blockade in patients with stable angina pectoris].

J Meluzín, M Novák
I. interní klinika fakultní nemocnice s poliklinikou U svaté Anny, Brno.

In 20 patients with stable angina II-III according to NYHA by means of ergometry the effect of short-term administration of dilthiazem (90 mg in three doses), placebo and isradipine (5 mg in three doses) in block of beta-receptors of the sympathetic nerve (metipranolol 3 x 10 mg/day) was compared. As compared with placebo, dilthiazem and isradipine retarded significantly the development of stenocardia, reduced the S-T depression in lead V5 and increased the total work output during ergometry. Based on the results of this and previous work (9) it may be stated that concurrent administration of metipranolol reduced the frequency of side-effects of isradipine and prevented the reflex rise of the heart rate following its short-terms administration. The authors conclude that starting treatment of stable angina with isradipine is safer and more effective in combination with metipranolol than when monotherapy is used. Dilthiazem must be administered with metipranolol carefully with regard to possible development of severe bradycardia and its suitable dose should be established by titration.

Keywords: Adult; Aged; Angina Pectoris, drug therapy, ; Calcium Channel Blockers, therapeutic use, ; Dihydropyridines, therapeutic use, ; Diltiazem, therapeutic use, ; Double-Blind Method; Electrocardiography, drug effects, ; Exercise Test; Heart Rate, drug effects, ; Humans; Isradipine; Male; Metipranolol, therapeutic use, ; Middle Aged

Published: February 1, 1992  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Meluzín J, Novák M. [Comparison of the effects of diltiazem and isradipine in adrenergic beta receptor blockade in patients with stable angina pectoris]. Vnitr Lek. 1992;38(2):122-128.
Download citation




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.